Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

about

MiR-93-5p Promotes Cell Proliferation through Down-Regulating PPARGC1A in Hepatocellular Carcinoma Cells by Bioinformatics Analysis and Experimental Verification.

P2860

Q47716490-A2CAF30F-12A0-45EF-AB10-D98F12F95A4B

P2860

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

Item

http://www.wikidata.org/entity/Q47869247

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@en

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@nl

type

Item

label

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@en

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@nl

prefLabel

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@en

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@nl

P1476

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

@en

P2093

Emilie Wang

http://www.w3.org/2001/XMLSchema#string

Jennifer Eatrides

http://www.w3.org/2001/XMLSchema#string

Nishi Kothari

http://www.w3.org/2001/XMLSchema#string

Richard Kim

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016

Global cancer statistics, 2012

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.

A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.

P304

1073274817729243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1177/1073274817729243

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975834

http://www.w3.org/2001/XMLSchema#string

P921

hepatocellular carcinoma

liver cancer

P932

5937243

http://www.w3.org/2001/XMLSchema#string

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

about

P2860

P2860

Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932